Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37360768/
Rearranged during transfection ( RET ) is a protooncogene that encodes for receptor tyrosine kinase with downstream effects on multiple cellular pathways. Activating RET alterations can occur and lead to...
Conclusion: Selpercatinib has led to a paradigm change in the management of RET fusion-positive solid tumors including NSCLC and thyroid cancer. Its current tissue-agnostic approval highlights the potential it has in different tumor types. Multiple studies are ongoing with the aim of exploring selpercatinib use in other disease settings and...
-
Advances in RET Therapy2yrKey Points • Source: Therapeutic Advances in Medical Oncology • Conclusion: “Selpercatinib has led to a paradigm change in the management of RET fusion-positive solid tumors including NSCLC and thyroid cancer. Its current tissue-agnostic Show More
Classification of Thyroid Tumors Based on DNA Methylation Patterns - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37392021/
Our data provide novel insights into the epigenetic alterations of thyroid tumors. Since our classification method relies on a fully unsupervised machine learning approach for subtype discovery, our results offer...
Conclusions: Our data provide novel insights into the epigenetic alterations of thyroid tumors. Since our classification method relies on a fully unsupervised machine learning approach for subtype discovery, our results offer a robust background to support the classification of thyroid neoplasms based on methylation patterns.
Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours - Targeted Oncology
Source : https://link.springer.com/article/10.1007/s11523-023-00974-6
Background RET plays an oncogenic role, and its aberrations are potentially actionable. However, they have seldom been reported in tumours other than lung or thyroid cancers. The correlation of RET...
Conclusions: Albeit rarely, RET aberrations can be found in digestive tract tumours. Patients with RET-aberrant tumours have a blunted response to ICPi and a comparable prognosis as compared with RET-wild type tumours. Together, these results provide insights into this rare but potentially actionable target in digestive tract tumours.
Additional exclusions of ROS1 fusions | LCTT
US FDA ; a regulatory authority has the right and responsibility to harmonize the use of ICIs in these actionable driver mutations
Conclusions/Relevance: We review the effectiveness of ICIs in never-smoker predominant NSCLC with driver mutations (EGFR, ALK, ROS1, RET, HER2) and question whether exclusion of ROS1 fusion would put cemiplimab at a competitive disadvantage given the requirement for insurance to prove ROS1 fusion negativity. We further discuss whether the US...
Molecular alterations of driver genes in non-small cell lung cancer
Source : https://www.excli.de/index.php/excli/article/view/6122
EXCLI Journal - Experimental and Clinical Sciences, International Online Journal for Advances in Sciences
Conclusions/Relevance: The molecular diagnostics of NSCLC using modern methods, like next-generation sequencing, is essential in estimating targeted, personalized therapy. In recent years, a breakthrough in understanding the importance of molecular studies for the precise treatment of NSCLC has been observed. Many new drugs were approved,...